Telling doctors the generic is not the same: a EUR 25M disparagement fine

A pharmaceutical company was fined EUR 25M, upheld at EUR 21M on appeal, for what its sales force told healthcare professionals about a competitor’s generic. The message was that the generic did not have the same composition, the same quantity of active ingredient, or the same size as the branded product, framed to suggest that switching carried risk. The statements sounded factual and specific. Without an evidence basis sufficient to support the implied conclusion, they were treated as unlawful disparagement.

This is one of the quieter ways a single line creates liability. It does not read as an attack. It reads as informed, helpful, technical detail. That is exactly what makes it dangerous.

Why a factual-sounding comparison becomes disparagement

Disparagement law, and the advertising and professional-conduct rules around it, do not require a falsehood in the literal sense. They require that a claim about a competitor be fair, balanced, and supportable. A comparison that selects the differences, implies they matter clinically or commercially, and omits the context that the products are nonetheless equivalent for the purpose at hand, can mislead even when each individual fact is true. The damage is in the implication, not a single false word.

The sales register makes it worse. A rep building trust, sounding precise, wanting to protect their product, will reach for specifics. Specifics about a competitor, deployed to steer a decision, are precisely what the rules scrutinize.

The pattern, and where it shows up

This is not only a pharma problem. The same shape appears wherever a salesperson, in writing, characterizes a competitor’s product to win a deal.

Each is a negative factual claim about a named competitor, sent in writing, to influence a buyer. That is the category courts and regulators treat most strictly.

Where a pre-send check fits

The honest fix here is usually not a rewrite, it is restraint: a claim whose entire content is an unsupported attack on a competitor has no compliant version, and the safe move is to remove it. A pre-send check flags the disparaging comparison as it is written and prompts the writer to drop it or stand it up with evidence, before it reaches the customer. It is built for the enthusiastic rep who does not realize “their product is not the same” is a legal claim, not a sales point. It complements the archive that would otherwise hold the line as an exhibit. See how this maps to compliance teams.

The takeaway

Telling a customer a competitor “is not the same”, without the evidence to back the implication, is one of the most expensive sentences a sales team can write. Treat negative claims about named competitors as legal claims, and check them before send.